Epoetin (specifically epoetin alfa and its biosimilar epoetin alfa-epbx) is an erythropoiesis-stimulating agent (ESA) and hematopoietic growth factor used primarily to manage symptomatic anemia in patients with lower-risk Myelodysplastic Syndromes (MDS).
Key Clinical Pearls for BCOP Prep:
- Mechanism & Goal: It stimulates the production of red blood cells to increase hematocrit and reduce the need for RBC transfusions. Doses are titrated to maintain a hemoglobin level of 10–12 g/dL.
- Predictive Response: The best clinical response occurs when the patient’s baseline endogenous serum erythropoietin (EPO) level is < 500 units/L and pretreatment transfusion requirements are low (< 2 units/month).
- Dosing: Doses in MDS are typically much higher than those used for chemotherapy-induced anemia, often starting at 300 units/kg SQ three times weekly.
- Disease Modification: Importantly, ESAs do not change the natural history of MDS, nor do they affect overall survival or the risk of progression to Acute Myeloid Leukemia (AML).
If a patient has an EPO level > 500 units/L or fails to respond to Epoetin, Luspatercept is generally the preferred next step, provided ring sideroblasts are present.
Would you like to review the specific clinical trial data that distinguishes Epoetin from Luspatercept in the frontline setting?
Links